Jerusalem, 19 November, 2025 (TPS-IL) — Israeli medical technology company IceCure Medical Ltd. has won regulatory approval in Switzerland for its ProSense Cryoablation System, allowing treatment of malignant and benign tumors in the breast, lung, liver, kidney, and musculoskeletal system. The Swissmedic clearance comes after the FDA recently authorized the system for low-risk breast cancer in the U.S.
IceCure’s minimally invasive system uses liquid nitrogen to destroy tumors, reducing surgical risks and enabling office-based procedures for patients across Europe.
Eyal Shamir, IceCure’s CEO, said the approval “enhances our commercial momentum and brings us closer to making ProSense a standard-of-care option to surgery globally.”